As a likely consequence of its capacity to interfere with biochemical events present in cells throughout the body, inorganic lead exerts a wide spectrum of multisystemic adverse effects. These health impacts range from subtle, subclinical changes in function to symptomatic, life-threatening intoxication. In recent years, research conducted on lead-exposed adults has increased public health concern over the toxicity of lead at low dose. These findings support a reappraisal of the levels of lead exposure, sustained for either short or extended periods of time, that may be safely tolerated in the workplace. In this article we offer health-based recommendations on the management of lead-exposed adults aimed at primary and secondary prevention of lead-associated health problems. As noted in the introduction to this mini-monograph ([@b68-ehp0115-000463]) the authors of this article are an independent subgroup of an expert panel (8 of 13 members) originally convened by the Association of Occupational and Environmental Clinics ([www.aoec.org](www.aoec.org)) to address these management issues. In deriving the recommendations in this article, we took note of a body of literature that establishes the potential for adverse health effects at blood lead concentrations or exposure levels permissible under current workplace regulations established in the 1970s by the U.S. Occupational Safety and Health Administration (OSHA). These regulations generally require removal from lead exposure when whole-blood lead concentrations exceed 50 or 60 μg/dL. These values are considerably above blood lead concentrations of the general population of the United States, which had a geometric mean of 12.8 μg/dL in the late 1970s ([@b48-ehp0115-000463]), and a recent value of 1.45 μg/dL \[U.S. [@b5-ehp0115-000463]\].

In setting forth our perspective on the recommended medical management of adult lead exposure, the narrative of this article focuses on four categories of health effects---hypertension, decrement in renal function, cognitive dysfunction, and adverse reproductive outcome---that have been the subject of much recent research. The discussion of these end points highlights those studies, that by virtue of their design and scope, were particularly influential in establishing the authors' concerns regarding the potential for adverse health effects at low to moderate levels of lead exposure in adults. Collectively, these effects support the preventive medical management strategies that are recommended in the tables. A review of the extensive literature on the health effects of lead is beyond the scope of this article, but the reader is referred to reviews on the cardiovascular and cognitive impacts of lead on adults that appear elsewhere in this mini-monograph ([@b50-ehp0115-000463]; [@b75-ehp0115-000463]), as well as a review on recent lead literature prepared by the U.S. Environmental Protection Agency (EPA) for its Air Quality Criteria for Lead ([@b85-ehp0115-000463]).

[Table 1](#t1-ehp0115-000463){ref-type="table"} is a summary of the adverse health risks associated with different blood lead concentrations and presents corresponding medical management recommendations that range from discussion of risks and reduction of lead exposure at low levels to removal from lead exposure accompanied by probable chelation therapy at the highest levels. The designation of risks as either "short-term" or "long-term," depending on whether the risks are associated with exposure lasting less than or more than 1 year, reflects a qualitative understanding of the duration of lead exposure that may be required to elicit certain adverse health effects of lead. For some of the long-term risks, such as hypertension, research employing noninvasive K-shell X-ray fluorescence measurement of lead in bone, a biomarker of long-term cumulative exposure, suggests that several years of sustained elevations in blood lead may be necessary for a significant risk to emerge. The use of 1 year as a cut-point in the table is not intended to represent a sharp division, in terms of cumulative dose, between what might constitute a short-term versus a long-term risk nor does it imply that a significant long-term risk begins to exist as soon as 1 year is surpassed. Blood lead, a measure of the amount of lead circulating in the tissues, reflects both recent exogenous exposure as well as endogenous redistribution of lead stored in bone.

The categorization of risks in [Table 1](#t1-ehp0115-000463){ref-type="table"} by discrete intervals of blood lead concentration is a qualitative assessment. In clinical practice, substantial interindividual variability in the susceptibility to symptomatic adverse effects of lead is commonly observed. Factors that might influence the risk of lead toxicity in adults include preexisting disease affecting relevant target organs (e.g., hypertension, renal disease, or neurologic dysfunction), nutritional deficiencies that modify the absorption or distribution of lead (e.g., low dietary calcium or iron deficiency), advanced age, and genetic susceptibility. Although recent studies suggest that polymorphisms in specific genes may modify the toxicokinetics and renal effects of lead ([@b83-ehp0115-000463]; [@b90-ehp0115-000463]; [@b97-ehp0115-000463]), research findings at present are insufficient to conclusively identify genotypes that confer increased risk.

Health Effects at Low Dose
==========================

Hypertension
------------

Animal investigations support a pressor effect of lead at low dose ([@b15-ehp0115-000463]; [@b20-ehp0115-000463]; [@b86-ehp0115-000463]). Epidemiologic investigations conducted in large general population samples (e.g., [@b24-ehp0115-000463]; [@b47-ehp0115-000463]; [@b58-ehp0115-000463]; [@b71-ehp0115-000463]) suggest lead may elevate blood pressure in adults at blood lead concentrations \< 20 μg/dL. In some human studies of the link between blood lead and blood pressure, the relationship appeared to be influenced by subjects' sex or race (e.g., [@b10-ehp0115-000463]; [@b80-ehp0115-000463]; [@b87-ehp0115-000463]). Three meta-analyses of studies examining the relationship between blood lead and blood pressure found relatively consistent effects of blood lead on blood pressure. The studies showed statistically significant coefficients for a 2-fold increase in blood lead of 1.0 mmHg ([@b49-ehp0115-000463]; [@b78-ehp0115-000463]) or 1.25 mmHg ([@b72-ehp0115-000463]) for systolic blood pressure, and 0.6 mmHg for diastolic blood pressure ([@b49-ehp0115-000463]; [@b78-ehp0115-000463]). The study populations analyzed in these meta-analyses included many with blood lead concentrations \< 20 μg/dL.

Further support for the impact of low-level lead exposure on blood pressure has emerged from studies employing K-shell X-ray fluorescence measurement of lead in bone, a biomarker of long-term cumulative lead exposure. In two major studies drawn from samples of the general population, bone lead concentration was a significant predictor of the risk of hypertension ([@b29-ehp0115-000463]; [@b33-ehp0115-000463]). Findings from the study by [@b29-ehp0115-000463] illustrate the associated risk. In that general population sample of middle-aged to elderly men (*n* = 590), the average blood lead concentration was 6.3 μg/dL. On the basis of the subjects' ages (mean 67 ± 7.2 years), it may be expected that they lived most of their adult lives at a time when the blood lead concentration of the general population ranged from 10 to 25 μg/dL ([@b28-ehp0115-000463]; [@b40-ehp0115-000463]; [@b44-ehp0115-000463]). Comparing the lowest with the highest quintile of bone lead among that cohort, a tibia bone lead increment of 29 μg/g was associated with a 1.5 odds ratio (OR) for hypertension \[95% confidence interval (CI), 1.1--1.8\]. Given the slope of 0.05 that has described the linear relationship between tibia bone lead concentration and cumulative blood lead index in subjects with chronic lead exposure in many studies ([@b30-ehp0115-000463]), this increment in bone lead is roughly equivalent to a cumulative blood lead index of 580 μg/dL · years (i.e., 29 μ 0.05 = 580). Considered in the context of a 40-year working lifetime, the risk of lead-associated hypertension may be significantly reduced by preventive measures that lower chronic workplace blood lead concentrations from the 20s and 30s μg/dL range to \< 10 μg/dL. For example, a change in average workplace blood lead concentration from 25 to 10 μg/dL over a 40-year working lifetime would reduce a worker's cumulative blood lead index by 600 μg/dL · years, slightly more than the 580 μg/dL · years cited above.

Hypertension is a significant risk factor for cardiovascular and cerebrovascular mortality. As reviewed in an accompanying article in this mini-monograph ([@b50-ehp0115-000463]), studies conducted in general population cohorts have consistently observed a positive association between lead exposure and cardiovascular disease. Because of their size and design, studies derived from the National Health and Nutrition Evaluation Surveys (NHANES) are particularly notable. A 16-year longitudinal analysis of the general population cohort studied between 1976 and 1980 as part of NHANES II found that blood lead concentrations of 20--29 μg/dL at baseline were associated with 39% increased mortality from circulatory system disease compared with subjects with blood lead \< 10 μg/dL \[relative risk (RR) 1.39; 95% CI, 1.01--1.91\] ([@b39-ehp0115-000463]). Two studies recently examined the longitudinal relationship between blood lead concentration and cardiovascular mortality among participants in NHANES III. In a 12-year longitudinal study of participants in NHANES III, ≥ 40 years of age (*n* = 9,757), the subgroup with blood lead concentration ≥ 10 μg/dL (median, 11.8) had a relative risk of cardiovascular mortality of 1.59 (95% CI, 1.28--1.98) compared with subjects with blood lead \< 5 μg/dL ([@b67-ehp0115-000463]). In a 12-year longitudinal analysis of subjects ≥ 17 years of age (*n* = 13,946), the relative risk for cardiovascular mortality was 1.53 (95% CI, 1.21--1.94), comparing a blood lead of 4.92 μg/dL (80th percentile of the distribution) with a blood lead of 1.46 μg/dL (20th percentile of the distribution) ([@b43-ehp0115-000463]).

Renal effects
-------------

Renal injury that appears after acute high-dose lead exposure may include reversible deficits in proximal tubular reabsorption and prerenal azotemia induced by renal vasoconstriction and/or volume depletion (Coyle et al. 200; [@b91-ehp0115-000463]). In a minority of exposed individuals, years of chronic, high-dose lead exposure may result in chronic lead nephropathy, a slowly progressive interstitial fibrosis characterized by scant proteinuria ([@b37-ehp0115-000463]). Epidemiologic investigations of renal function in workers with lower levels of chronic lead exposure have yielded variable findings. For example, in a cohort of approximately 800 current and former lead workers with mean blood lead of 32 ± 15 μg/dL, there was no significant linear relationship between blood lead concentration and two measures of renal function, serum creatinine and creatinine clearance ([@b89-ehp0115-000463]). There was an interaction between age and tibia lead concentration, a biomarker of cumulative lead exposure, on these same biomarkers, resulting in a trend toward worse renal function with increasing bone lead in the oldest tercile of workers (\> 46 years of age) but improved renal function with increasing bone lead in the youngest workers (≤ 36 years of age). The authors suggested that lead-induced hyperfiltration, a finding noted in other studies, might presage the eventual development of lead-induced renal insufficiency. Both blood lead and tibia lead were correlated with increased urinary *N*-acetyl-β-[d]{.smallcaps}-glucosaminidase (NAG), a biomarker of early biological effect on the renal tubule, but in an analysis of a smaller subset of the lead workers (*n* = 190) that controlled for the relatively low levels of urinary cadmium (1.1 ± 0.78 μg/g creatinine), only the relationship with tibia lead and NAG remained significant ([@b89-ehp0115-000463]). Among a cohort of 70 active lead workers with a median blood lead concentration of 32 μg/dL (range, 5--47), there were modest correlations between blood lead and urinary β-2-microglobulin (*r* = 0.27; *p* = 0.02), and between cumulative blood lead index and NAG (*r* = 0.25; *p* = 0.04) ([@b16-ehp0115-000463]).

Several studies conducted in general population samples have reported an association between blood lead concentration and common biomarkers of renal function (serum creatinine and creatinine clearance). In a cross-sectional investigation of a subcohort of middle-aged to elderly men enrolled in the Normative Aging Study (*n* = 744), there was a negative correlation between blood lead (mean, 8.1 ± 3.9 μg/dL; range, \< 4.0--26.0 μg/dL) and measured creatinine clearance, after natural log transformation of both variables and adjustment for other covariates ([@b55-ehp0115-000463]). Among an adult population that included subjects with environmental cadmium exposure \[*n* = 965 men (geometric mean blood lead, 11.4 μg/dL; range, 2.3--72.5 μg/dL); *n* = 1,016 women (geometric mean blood lead, 7.5 μg/dL; range, 1.7--60.3 μg/dL)\], log-transformed blood lead concentration was inversely correlated with measured creatinine clearance ([@b79-ehp0115-000463]). In a population-based study of Swedish women 50--59 years of age (*n* = 820), low levels of blood lead (mean 2.2 μg/dL; 5th--95th percentiles, 1.1--4.6 μg/dL) were inversely correlated with creatinine clearance and glomerular filtration rate, after adjusting for age, body mass index, urinary or blood cadmium, hypertension, diabetes, and regular use of nonsteroidal anti-inflammatory drug (NSAID) medication ([@b1-ehp0115-000463]).

Individuals with other risk factors for renal disease, notably hypertension and diabetes, may be more susceptible to an adverse impact of low-level lead exposure on renal function. Among adults participating in NHANES III (*n* = 15,211), blood lead was a risk factor for elevated serum creatinine (defined as ≥ 99th percentile of the analyte's race and sex specific distributions, generally \> 1.2--1.5 mg/dL) and "chronic kidney disease" (defined as an estimated glomerular filtration rate \< 60 mL/min) only among subjects with hypertension (*n* = 4813) ([@b46-ehp0115-000463]). Compared with hypertensives in the lowest quartile of blood lead (range, 0.7--2.4 μg/dL), hypertensive subjects in the next highest quartile of blood lead (range, 2.5--3.8 μg/dL) had a covariate adjusted OR for elevated serum creatinine of 1.47 (95% CI, 1.03--2.10) and for chronic kidney disease of 1.44 (95% CI, 1.00--2.09). At the next highest quartile of blood lead (range, 3.9--5.9 μg/dL), the covariate-adjusted OR for elevated serum creatinine was 1.80 (95% CI, 1.34--2.42), and for chronic kidney disease it was 1.85 (95% CI, 1.32--2.59). In a subcohort of middle-aged to elderly men participating in the Normative Aging Study (*n* = 427, blood lead 4.5 ± 2.5 μg/dL), multiple regression analysis revealed that log-transformed blood lead was positively correlated with serum creatinine in hypertensive but not normotensive subjects ([@b84-ehp0115-000463]). In a longitudinal study of this cohort over a mean of 6 years, an interaction between lead and diabetes yielded a positive association between baseline blood lead concentration and change in serum creatinine that was strongest in diabetic subjects ([@b84-ehp0115-000463]). An interaction with diabetes was also present in the association of tibial lead concentration with longitudinal change in serum creatinine ([@b84-ehp0115-000463]). Although these general population studies are consistent with an adverse effect of lead exposure on renal function at notably low levels, the extent to which diminished renal function may itself result in increased body lead burden has not been fully elucidated.

Cognitive dysfunction
---------------------

A few studies examining relatively small numbers of workers (*n* ≤ 100) with blood lead concentrations ranging approximately 20--40 μg/dL have associated lead exposure with subclinical decrements in selective domains of neurocognitive function ([@b2-ehp0115-000463]; [@b23-ehp0115-000463]; [@b41-ehp0115-000463]; [@b81-ehp0115-000463]). Among a large cohort of current and former inorganic lead workers studied in Korea, a cross-sectional analysis (*n* = 803 workers) ([@b69-ehp0115-000463]) and a 3-year longitudinal analysis (*n* = 576 workers) ([@b70-ehp0115-000463]) found that blood lead concentrations across the approximate range of 20--50 μg/dL were associated with subclinical neurocognitive deficits. Among a small population of former lead workers (*n* = 48) and age-matched controls with similar blood lead concentrations (approximately 5 μg/dL in both groups; range, 1.6--14.5 μg/dL; mean age, 39.8 years), increases in current blood lead concentration within the entire study population were correlated with poorer performance on several tests of neurocognitive function but on only one measure was cumulative lead exposure (measured in the workers) associated with poorer performance ([@b94-ehp0115-000463]).

In the population-based sample of adults 20--59 years of age participating in the NHANES III study (*n* = 4937), there was no relationship between blood lead concentration (geometric mean, 2.51 μg/dL) and covariate-adjusted performance on neurocogntive function ([@b36-ehp0115-000463]). However, significant associations have emerged in some studies of older adults with slightly higher blood lead concentrations. In a rural subset of elderly women (mean age, 71.1 ± 4.7 years; *n* = 325) with background, community lead exposure (geometric mean blood lead concentration, 4.8 μg/dL; range, 1--21 μg/dL), certain measures of neuropsychologic function (Trailmaking part B and Digit Symbol test) were performed more poorly by women in the upper 15th percentile of blood lead (blood lead ≥ 8 μg/dL, *n* = 38; [@b45-ehp0115-000463]). However, in the slightly younger subset of elderly women who resided in an urban area (mean age, 69.4 ± 3.8 years; *n* = 205), no relationship between blood lead (geometric mean, 5.4 μg/dL) and neuropsychologic performance was discernible ([@b45-ehp0115-000463]). In a general population sample of middle-aged to elderly men (*n* = 141; mean age, 66.8 ± 6.8 years) with a mean blood lead concentration of 5.5 ± 3.5 μg/dL examined as part of the Normative Aging Study, increased blood lead concentration was associated with poorer performance on neuropsychologic assessment of memory, verbal ability, and mental processing speed ([@b56-ehp0115-000463]). In a larger subset of men (*n* = 736; mean age, 68.2 ± 6.9 years) from the Normative Aging Study assessed with the Mini-Mental Status Examination (MMSE), the OR for having a test score associated with an increased risk of dementia was 3.4 (95% CI, 1.6--7.2) comparing the mean blood lead of the highest quartile (mean, 8.9 μg/dL) to that of the lowest quartile (mean, 2.5 μg/dL) ([@b96-ehp0115-000463]). There was a positive interaction between age and blood lead, which is consistent with a lead-associated acceleration in age-related neurodegeneration.

As reviewed in an accompanying article in this mini-monograph ([@b75-ehp0115-000463]), there is evidence that at low levels of lead exposure, biomarkers of cumulative lead exposure, such as lead in bone, may be associated with an adverse impact on neurocognitive function that is not reflected by measurement of lead in blood. Among subjects from the Normative Aging Study (*n* = 466; mean age, 67.4 ± 6.6 years) examined for longitudinal change in MMSE score over an average of 3.5 ± 1.1 years, higher patella bone lead concentrations, a biomarker of cumulative lead exposure, predicted a steeper decline in performance ([@b93-ehp0115-000463]). By comparison, baseline blood lead concentration (median, 4 μg/dL; interquartile range = 3, 5) did not predict change in MMSE score. In a longitudinal analysis of performance on a battery of cognitive tests in a subset of the Normative Aging Study, bone lead measurements were predictive of worsening performance over time on tests of visuospatilal/visuomotor ability ([@b92-ehp0115-000463]). In a cross-sectional analysis of 985 community dwelling residents 50--70 years of age, increasing tibia bone lead concentrations were significantly associated with decrements in cognitive function, whereas an impact of blood lead (mean, 3.46 ± 2.23 μg/dL) was not apparent ([@b74-ehp0115-000463]).

Reproductive outcome in women
-----------------------------

Adverse effects on reproductive outcome constitute a special risk of lead exposure to women of reproductive age. A nested case--control study examined the association of blood lead concentration with spontaneous abortion in a cohort of 668 pregnant women seeking pre-natal care in Mexico City ([@b3-ehp0115-000463]). After matching for maternal age, education, gestational age at study entry, and other covariates, the OR for spontaneous abortion before 21 weeks gestation was 1.13 (95% CI, 1.01--1.30) for every 1 μg/dL increase in blood lead across the blood lead range of 1.4--29 μg/dL. Compared with the reference category of \< 5 μg/dL of blood lead, women whose blood lead levels were 5--9, 10--14, and \> 15 μg/dL had ORs for spontaneous abortion of 2.3, 5.4, and 12.2, respectively (test for trend, *p* = 0.03). Although several earlier studies failed to detect this substantial impact, they may have been subject to methodologic limitations not present in the Mexico City investigation ([@b26-ehp0115-000463]).

Several studies have found that lead exposure during pregnancy affects child physical development measured during the neonatal period and early childhood. In an extensively studied cohort of 272 full-term, parturient women from Mexico City with environmental lead exposure common to the region (mean maternal blood lead, 8.9 ± 4.1 μg/dL; mean tibia bone lead, 9.8 ± 8.9 μg/g; range, 12--38 μg/g), every increase of 10 μg/g in maternal tibia lead was associated with a 73-g (95% CI, 25--121) decrease in birth weight ([@b18-ehp0115-000463]). The impact of tibia bone lead on birth weight was nonlinear and was most pronounced in mothers with the highest quartile of bone lead (\> 15--38 μg/g) where the decrement relative to the lowest quartile was estimated to be 156 g. Primarily in the same cohort, a maternal patella lead concentration \> 24.7 μg/g was associated with an OR of 2.35 (95% CI, 1.26--4.40) for a neonate with one category smaller head circumference at birth, assessed as a five-category--ordered variable ([@b25-ehp0115-000463]). In a different Mexico City cohort, each doubling of maternal blood lead at 36 weeks of pregnancy (geometric mean, 8.1 μg/dL; 25th--75th percentile, 5--12 μg/dL) was associated with a decrease of 0.37 cm (95% CI, 0.57--0.17) in the head circumference of a 6-month-old infant ([@b64-ehp0115-000463]).

Prenatal lead exposure assessed by umbilical cord blood lead concentration has been inconsistently associated with an adverse effect on neurobehavioral development in childhood. However, recent studies suggest that mobilization of maternal bone lead during pregnancy may contribute to fetal lead exposure in ways that may be incompletely reflected by the single measurement of umbilical cord whole-blood lead ([@b7-ehp0115-000463]; [@b82-ehp0115-000463]). In a prospective study conducted in Mexico City of 197 mother--infant pairs, a statistically significant adverse effect of umbilical cord blood lead (mean, 6.7 ± 3.4 μg/dL; range, 1.2--21.6 μg/dL) was also accompanied by an independent adverse effect of maternal bone lead burden on the 24-month Mental Development Index (MDI) of the Bayley Scales of Infant Development, which decreased 1.6 points (95% CI, 0.2--3.0) for every 10-μg/g increase in maternal patellar lead (mean, 17.9 ± 15.2 μg/g; range, \<1--76.6 μg/g) ([@b19-ehp0115-000463]).

A prospective study that measured maternal plasma lead and maternal whole-blood lead during pregnancy found that maternal plasma lead during the first trimester was the stronger predictor of infant mental development at 24 months of age ([@b31-ehp0115-000463]). In this cohort, first trimester maternal plasma lead was 0.016 ± 0.014 μg/dL and first trimester maternal whole-blood lead was 7.07 ± 5.10 μg/dL (*n* = 119). Adjusting for covariates that included maternal age, maternal IQ, child sex, childhood weight and height for age, and childhood whole-blood lead at 24 months, an increase of one SD in log~e~ (natural log)--transformed plasma lead in the first trimester was associated with a 3.5-point decrease in score on the 24-month MDI of the Bayley Scales of Infant Development. The corresponding impact of one SD increase in log~e~ maternal whole blood during the first trimester was a 2.4-point decrease in the 24-month MDI. The logarithmic relationship between maternal plasma and blood lead concentrations and infant MDI indicated that the strongest effects occurred among mothers with the lowest plasma and blood lead concentrations.

Two long-term prospective studies that conducted multiple measurements of maternal blood lead during pregnancy and childhood have identified an adverse impact of low-level prenatal lead exposure on postnatal neurobehavioral development extending beyond infancy. Applying a repeated measures linear regression technique to analysis of age-appropriate IQ test data obtained in 390 children 3--7 years of age, the Yugoslavia Prospective Lead Study found independent adverse effects of both prenatal and postnatal blood lead. After controlling for the pattern of change in postnatal blood lead and other covariates, IQ decreased 1.8 points (95% CI, 1.0--2.6) for every doubling of prenatal blood lead, which was assessed as the average of maternal blood lead at midpregnancy and delivery (mean, 10.2 ± 14.4 μg/dL; *n* = 390) ([@b88-ehp0115-000463]). The Mexico City Prospective Lead Study used generalized linear mixed models with random intercept and slope to assess the impact on IQ measured at 6--10 years of age of blood lead measurements systematically obtained during weeks 12, 20, 24, and 36 of pregnancy, at delivery, and at multiple points throughout childhood ([@b66-ehp0115-000463]). Geometric mean blood lead during pregnancy was 8.0 μg/dL (range, 1--33 μg/dL; *n* = 150); from 1 through 5 years it was 9.8 μg/dL (2.8--36.4 μg/dL), and from 6 through 10 years it was 6.2 μg/dL (range, 2.2--18.6 μg/dL). IQ at 6 to 10 years of age, assessed by the Wechsler Intelligence Scale for Children---Revised, decreased significantly only with increasing natural-log third-trimester blood lead, controlling for other blood lead measurements and covariates. Every doubling of third trimester blood lead (geometric mean of maternal blood lead at weeks 28 and 36 = 7.8 μg/dL, 5th--95th percentile: range, 2.5--24.6 μg/dL) was associated with an IQ decrement of 2.7 points (95% CI, 0.9--4.4). Notably, the nonlinear (i.e., log-linear) relationships detected in the Yugoslavia and Mexico City studies indicate that across a maternal blood lead range of 1--30 μg/dL, an increase in blood lead from 1 to 10 μg/dL will account for more than half the IQ decrement.

Two independent cohorts have provided evidence that maternal lead burden during pregnancy may be associated with increased risk of pregnancy hypertension and/or elevated blood pressure during pregnancy. In a retrospective study of 3,210 women during labor and delivery, increasing umbilical cord blood lead levels (mean, 6.9 ± 3.3 μg/dL; range, 0--35 μg/dL) were associated with increased systolic blood pressure during labor (1.0 mmHg for every doubling of blood lead) and increased odds of hypertension (not further defined) recorded any time during pregnancy (OR = 1.3; 95% CI, 1.1--1.5) for every doubling of blood lead ([@b59-ehp0115-000463]). A prospective study of third trimester blood lead (geometric mean, 2.3 ± 1.4 μg/dL; range, 0.5--36.5 μg/dL) in 1,188 predominantly Latina immigrants showed that, in the immigrants, every doubling in blood lead was associated with increased third-trimester systolic blood pressure (1.2 mmHg; 95% CI, 0.5--1.9) and diastolic blood pressure (1.0 mmHg; 95% CI, 0.4--1.5) ([@b63-ehp0115-000463]). A study of a subset of the same cohort (*n* = 637) without regard to immigration status found that every 10-μg/g increase in calcaneus (heel) bone lead increased the OR of third trimester pregnancy hypertension (systolic \> 90 and/or diastolic \> 140 mmHg) by 1.86 (95% CI, 1.04--3.32) ([@b62-ehp0115-000463]).

Medical Surveillance for Lead-Exposed Workers
=============================================

The OSHA workplace standard for lead exposure in general industry (adopted in 1978) and a corresponding standard for lead exposure in construction trades (adopted in 1993) set forth medical surveillance requirements that include baseline and periodic medical examinations and laboratory testing. Details of the two standards, which establish distinct criteria for the implementation of surveillance, can be found on the OSHA website ([@b52-ehp0115-000463]). Because of the concern regarding adverse health effects of lead associated with the lower levels of exposure discussed in this article, we recommend a revised schedule of medical surveillance activities ([Table 2](#t2-ehp0115-000463){ref-type="table"}). Unlike the OSHA medical surveillance requirements, which apply only to workers exposed to airborne lead levels ≥ 30 μg/m^3^ as an 8-hr time-weighted average, the recommendations in [Table 2](#t2-ehp0115-000463){ref-type="table"} are intended to apply to all lead-exposed workers who have the potential to be exposed by lead ingestion, even in the absence of documented elevations in air lead levels ([@b73-ehp0115-000463]). As shown in [Table 2](#t2-ehp0115-000463){ref-type="table"}, the level of a worker's current blood lead measurement, as well as possible changes in lead-related exposure, influences the recommended time interval for subsequent blood lead measurements. Blood lead measurements should be obtained from a clinical laboratory that has been designated by OSHA as meeting the specific proficiency requirements of the OSHA lead standards. OSHA maintains a list of these laboratories on its website ([@b53-ehp0115-000463]). Venous blood should be used for biological monitoring of adult lead exposures, except where prohibited by medical or other reasons. Routine measurement of zinc protoporphyrin, a requirement of the OSHA lead standards, is not recommended in [Table 2](#t2-ehp0115-000463){ref-type="table"} because it is an insensitive biomarker of lead exposures in individuals with blood lead concentrations \<25 μg/dL ([@b54-ehp0115-000463]).

The content of the baseline or preplacement history and physical examination for lead-exposed workers should continue to follow the comprehensive scope set forth in the OSHA lead standard for general industry. Measurement of serum creatinine will identify individuals with chronic renal dysfunction who may be subject to increased health risks from lead exposure. With the potential exception of an annual blood pressure measurement and a brief questionnaire regarding the presence of medical conditions (such as renal insufficiency) that might increase the risk of adverse health effects of lead exposure, medical evaluations for lead-exposed workers should be unnecessary as long as blood lead concentrations are maintained \< 20 μg/dL. Annual education of lead workers regarding the nature and control of lead hazards, and ongoing access to health counseling regarding lead-related health risks are recommended as preventive measures.

Lead Exposure during Pregnancy and Lactation
============================================

As summarized earlier in this article, the recent findings concerning lead-related adverse reproductive outcomes render it advisable for pregnant women to avoid occupational or avocational lead exposure that would result in blood lead concentrations \> 5 μg/dL. Calcium supplementation during pregnancy may be especially important for women with past exposure to lead. Calcium decreases bone resorption during pregnancy ([@b32-ehp0115-000463]) and may minimize release of lead from bone stores and subsequent fetal lead exposure ([@b19-ehp0115-000463]).

Maternal body lead burden and external lead exposure influence the lead concentration of breast milk ([@b12-ehp0115-000463]; [@b21-ehp0115-000463]). The few studies that used ultraclean techniques and mass spectrometry analyses report human breast milk concentrations ranging from 0.6 to 3% of maternal blood lead ([@b14-ehp0115-000463]; [@b21-ehp0115-000463]; [@b42-ehp0115-000463]; [@b77-ehp0115-000463]). Using 1% as a guide, it can be estimated that nursing mothers with a blood lead concentration \< 20 μg/dL will have breast milk with a concentration \< 2 μg/L, a value that approximates the amount of lead in infant formula ([@b22-ehp0115-000463]). A recent randomized clinical trial among Mexican women with mean blood lead concentrations of approximately 9 μg/dL found that calcium supplementation during lactation may reduce the lead concentration of breast milk by 5--10% ([@b12-ehp0115-000463]). Breast feeding should be encouraged for almost all women ([@b13-ehp0115-000463]; [@b65-ehp0115-000463]; [@b76-ehp0115-000463]), with decisions concerning women with very high lead exposure addressed on an individual basis.

Medical Treatment of Elevated Blood Lead Concentration and Overt Lead Intoxication
==================================================================================

Removal from all sources of hazardous lead exposure, whether occupational or nonoccupational, constitutes the first and most fundamental step in the treatment of an individual with an elevated blood lead concentration. A careful history that inquires about a broad spectrum of potential lead sources is recommended ([@b51-ehp0115-000463]). Removal from occupational lead exposure will usually require transfer of the individual out of any environment or task that might be expected to raise the blood lead concentration of a person not using personal protective equipment above background levels (i.e., 5 μg/dL). If there has been a history of an affected individual bringing lead-contaminated shoes, work clothes, or equipment home from the workplace, evaluation of vehicles and the home environment for significant levels of lead-containing dust might be considered ([@b57-ehp0115-000463]). Although such "take-home" exposure might contribute to further lead exposure of the worker, it ordinarily poses more of a potential risk to young children and pregnant or nursing women who share the worker's home environment ([@b27-ehp0115-000463]; [@b61-ehp0115-000463]).

Medical treatment of individuals with overt lead intoxication involves decontamination, supportive care, and judicious use of chelating agents. Comprehensive discussion of such treatment is beyond the scope of this article but has been reviewed in recent medical toxicology texts ([@b34-ehp0115-000463], [@b35-ehp0115-000463]). A variety of chelating agents has been demonstrated to decrease blood lead concentrations and increase urinary lead excretion. A recent double-blind randomized clinical trial of oral chelation in young children with blood lead concentrations ranging from 22 to 44 μg/dL found that the drug succimer lowered blood concentrations transiently but did not improve cognitive function ([@b11-ehp0115-000463]; [@b60-ehp0115-000463]). Although anecdotal evidence suggests that chelation has been associated with improvement in symptoms and decreased mortality in patients with lead encephalopathy, controlled clinical trials demonstrating efficacy are lacking. Treatment recommendations are therefore mostly empiric, and decisions regarding the initiation of chelation therapy for lead intoxication have occasionally engendered controversy.

In our experience, adults with blood lead concentrations ≥ 100 μg/dL almost always warrant chelation, as levels of this magnitude are often associated with significant symptoms and may be associated with an incipient risk of encephalopathy or seizures. Occasionally, patients with very high blood lead concentrations may have no overt symptoms. Patients with blood lead concentrations of 80--99 μg/dL, with or without symptoms, can be considered for chelation treatment, as may some symptomatic individuals with blood lead concentrations of 50--79 μg/dL. These demarcations are imprecise, however, and decisions on chelation should be made on a case-by-case basis after consultation with an experienced specialist in occupational medicine or medical toxicology.

Hair lead analysis or measurement of urine lead concentration seldom provide exposure information of clinical value beyond that provided by the history and the measurement of blood lead concentration. Chelation initiated exclusively on the basis of hair or urine lead levels or chelation of asymptomatic individuals with low blood lead concentrations is not recommended.

Adults with overt lead intoxication will generally experience improvement in symptoms after removal from lead exposure and decline in blood lead concentration. This clinical observation on improvement in overt symptoms finds some support from the relatively limited number of studies that have examined the impact of naturally declining blood lead concentrations on cognitive function in occupationally exposed subjects ([@b6-ehp0115-000463]; [@b38-ehp0115-000463]; [@b95-ehp0115-000463]). Improvement or resolution of neurocognitive or neurobehavioral symptoms may sometimes lag the decline in blood lead concentration, possibly because of the relatively slower removal of lead from the central nervous system ([@b9-ehp0115-000463]; [@b17-ehp0115-000463]). The pace of improvement can be highly variable, and may range from weeks to a year or more depending on the magnitude of intoxication. Anecdotal experience and analogy to other forms of brain injury suggest a potential role for rehabilitative services (e.g., physical therapy, cognitive rehabilitation) in enhancing the prospect for recovery, and in demonstrating the capacity for safe return to work. Short-term improvement in neurocognitive function associated with a decline in blood lead concentration does not obviate concern that long-term cumulative lead exposure may nonetheless have a deleterious effect on cognitive reserve, and may accelerate age-related decline in cognitive function ([@b70-ehp0115-000463]; [@b93-ehp0115-000463]).

Additional Management Considerations
====================================

With appropriate engineering controls, safe work practices, and personal protective equipment, workers without a previous history of substantial lead exposure should be able to work with lead in a manner that minimizes the potential for hazardous levels of exposure. For such workers, elevations in blood lead concentration that result from unforeseen transient increases in exposure will often decline promptly once the exposure is controlled. However, in a worker with a long history of high exposure, redistribution of lead from a large internal skeletal burden may result in a prolonged elevation of blood lead concentration despite marked reductions in external lead dose.

The recommendations for management of adult lead exposure contained in this article are derived from consideration of risks to health, and have not been the subject of a cost-benefit analysis examining economic feasibility or social impacts. Nonmedical, socioeconomic factors will likely influence how workers, employers, and clinicians respond to the recommendations. In particular, the blood lead concentrations for which some major interventions, such as removal from lead exposure, are recommended are considerably lower than those explicitly specified in the current OSHA lead standards ([@b52-ehp0115-000463]). The OSHA standards do require an employer to implement reductions in exposure recommended by a physician who determines an employee has a "detected medical condition" that places him or her at increased risk of "material impairment to health." This nonspecific provision could form the basis for implementation of protective workplace action at the lower blood concentrations recommended by the authors. Nonetheless, clinicians should inform patients that such recommendations may be contested by an employer or an insurer, and could potentially jeopardize their job benefits or work status. Prudent case management that considers the worker's perspective on their unique health risks and employment situation will usually be advisable.

Interpretative Guidance for Clinical Laboratory Report Forms
============================================================

Clinical laboratories routinely offer brief interpretative guidance on the forms that report the result of blood lead concentrations. There is considerable variability among laboratories regarding the content of such guidance, and laboratories exercise their own discretion regarding the source and detail of the information they provide. Unlike the management guidance chart for childhood blood lead concentrations published by the [@b4-ehp0115-000463], which is often reproduced by clinical laboratories, no corresponding CDC guidance exists for blood lead concentrations measured in adults. Notwithstanding the limitations inherent in an abbreviated tabular format, [Table 3](#t3-ehp0115-000463){ref-type="table"} represents a guidance chart for adult blood lead measurements that is proposed for use by clinical laboratories.
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###### 

Health-based management recommendations for lead-exposed adults.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Blood lead level (μg/dL)   Short-term risks (lead exposure \< 1 year)                            Long-term risks (lead exposure ≥ 1 year)                                      Management
  -------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \< 5                       None documented                                                       None documented                                                               None indicated

  5--9                       Possible spontaneous abortion\                                        Possible spontaneous abortion\                                                Discuss health risks\
                             Possible postnatal developmental delay                                Possible postnatal developmental delay\                                       Reduce lead exposure for women who are or may become pregnant
                                                                                                   Possible hypertension and kidney dysfunction                                  

  10--19                     Possible spontaneous abortion\                                        Possible spontaneous abortion\                                                As above for BLL 5--9 μg/dL, plus:\
                             Possible postnatal developmental delay\                               Reduced birth weight\                                                         Decrease lead exposure\
                             Reduced birth weight                                                  Possible postnatal developmental delay\                                       Increase biological monitoring\
                                                                                                   Hypertension and kidney dysfunction\                                          Consider removal from lead exposure to avoid long-term risks if exposure control over an extended period does not decrease BLL \< 10 μg/dL, or if medical condition present that increases risk with continued exposure[a](#tfn2-ehp0115-000463){ref-type="table-fn"}
                                                                                                   Possible subclinical neurocognitive deficits                                  

  20--29                     Possible spontaneous abortion\                                        Possible spontaneous abortion\                                                Remove from lead exposure if repeat BLL measured in 4 weeks remains ≥ 20 μg/dL
                             Possible postnatal developmental delay\                               Possible postnatal developmental delay\                                       
                             Reduced birth weight                                                  Reduced birth weight\                                                         
                                                                                                   Hypertension and kidney dysfunction\                                          
                                                                                                   Possible subclinical neurocognitive deficits                                  

  30--39                     Spontaneous abortion\                                                 Spontaneous abortion\                                                         Remove from lead exposure
                             Possible postnatal developmental delay\                               Reduced birth weight\                                                         
                             Reduced birth weight                                                  Possible postnatal developmental delay\                                       
                                                                                                   Hypertension and kidney dysfunction\                                          
                                                                                                   Possible neurocognitive deficits\                                             
                                                                                                   Possible nonspecific symptoms[b](#tfn3-ehp0115-000463){ref-type="table-fn"}   

  40--79                     Spontaneous abortion\                                                 Spontaneous abortion\                                                         Remove from lead exposure\
                             Reduced birth weight\                                                 Reduced birth weight\                                                         Refer for prompt medical evaluation\
                             Possible postnatal developmental delay\                               Possible postnatal developmental delay\                                       Consider chelation therapy for BLL \>50 μg/dL with significant symptoms or signs of lead toxicity
                             Nonspecific symptoms[b](#tfn3-ehp0115-000463){ref-type="table-fn"}\   Nonspecific symptoms[b](#tfn3-ehp0115-000463){ref-type="table-fn"}\           
                             Neurocognitive deficits\                                              Hypertension\                                                                 
                             Sperm abnormalities                                                   Kidney dysfunction/nephropathy\                                               
                                                                                                   Subclinical peripheral neuropathy\                                            
                                                                                                   Neurocognitive deficits\                                                      
                                                                                                   Sperm abnormalities\                                                          
                                                                                                   Anemia\                                                                       
                                                                                                   Colic\                                                                        
                                                                                                   Possible gout                                                                 

  ≥ 80                       Spontaneous abortion\                                                 Spontaneous abortion\                                                         Remove from lead exposure\
                             Reduced birth weight\                                                 Reduced birth weight\                                                         Refer for immediate/urgent medical evaluation\
                             Possible postnatal developmental delay\                               Possible postnatal developmental delay\                                       Probable chelation therapy
                             Nonspecific symptoms[b](#tfn3-ehp0115-000463){ref-type="table-fn"}\   Nonspecific symptoms[b](#tfn3-ehp0115-000463){ref-type="table-fn"}\           
                             Neurocognitive deficits\                                              Hypertension\                                                                 
                             Encephalopathy\                                                       Nephropathy\                                                                  
                             Sperm abnormalities\                                                  Peripheral neuropathy\                                                        
                             Anemia\                                                               Neurocognitive deficits\                                                      
                             Colic                                                                 Sperm abnormalities\                                                          
                                                                                                   Anemia\                                                                       
                                                                                                   Colic\                                                                        
                                                                                                   Gout                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BLL, blood lead level.

Medical conditions that may increase the risk of continued exposure include chronic renal dysfunction (serum creatinine \> 1.5 mg/dL for men and \> 1.3 mg/dL for women, or proteinuria), hypertension, neurologic disorders, and cognitive dysfunction.

Nonspecific symptoms may include headache, fatigue, sleep disturbance, anorexia, constipation, arthralgia, myalgia, and decreased libido.

###### 

Health-based medical surveillance recommendations for lead-exposed workers.

  Category of exposure                                                     Recommendations
  ------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------
  All lead-exposed workers[a](#tfn5-ehp0115-000463){ref-type="table-fn"}   Baseline or preplacement medical history and physical examination, baseline
                                                                           BLL, serum creatinine
  BLL (μg/dL)                                                              
   \< 10                                                                   BLL every month for first 3 months of placement, or upon change in task to higher exposure, then BLL every 6 months
                                                                           If BLL increases ≥ 5 μg/dL, evaluate exposure and protective measures.
                                                                            Increase monitoring if indicated
                                                                           See [Table 1](#t1-ehp0115-000463){ref-type="table"} for pregnancy concerns
   10--19                                                                  As above for BLL \< 10 μg/dL, plus:
                                                                            BLL every 3 months
                                                                            Evaluate exposure, engineering controls, and work practices
                                                                            Consider removal (see [Table 1](#t1-ehp0115-000463){ref-type="table"})
                                                                            Revert to BLL every 6 months after 3 BLLs \< 10 μg/dL
   ≥ 20                                                                    Remove from exposure if repeat BLL measured in 4 weeks remains ≥ 20 μg/dL, or if first BLL ≥ 30 μg/dL (see [Table 1](#t1-ehp0115-000463){ref-type="table"})
                                                                           Monthly BLL testing
                                                                           Consider return to lead work after 2 BLLs \< 15 μg/dL a month apart, then monitor as above

BLL, blood lead level.

Lead-exposed means handling or disturbing materials with a significant lead content in a manner that could reasonably be expected to cause potentially harmful exposure through inhalation or ingestion.

###### 

Recommended interpretive guidance for clinical laboratories reporting adult blood lead concentrations.

  ------------------------------------------------------------------------------------------------------------------------------------------------------
  Blood lead level (μg/dL)   Management recommendations and requirements[a](#tfn7-ehp0115-000463){ref-type="table-fn"} for adults
  -------------------------- ---------------------------------------------------------------------------------------------------------------------------
  \< 5                       No action needed

  5--9                       Discuss health risks\
                             Reduce exposure for pregnancy

  10--19                     Discuss health risks. Decrease exposure. Monitor BLL\
                             Remove from exposure for pregnancy, certain medical conditions, long-term risks

  20--29                     Remove from exposure if repeat BLL in 4 weeks remains ≥ 20 μg/dL

  30--79                     Remove from exposure. Prompt medical evaluation and consultation advised for BLL \> 40 μg/dL OSHA requirements may apply\
                             Chelation not indicated unless BLL \>50 μg/dL with significant symptoms

  ≥ 80                       Urgent medical evaluation and consultation indicated\
                             OSHA requirements may apply\
                             Chelation may be indicated if symptomatic and/or BLL ≥100 μg/dL
  ------------------------------------------------------------------------------------------------------------------------------------------------------

BLL, blood lead level. Primary management of lead poisoning is source identification and removal from exposure. A single BLL does not reflect cumulative body burden or predict long-term effects.

Refer to OSHA general industry and construction lead standards for occupational exposure.

[^1]: MJK is an independent consultant who has provided paid consultation to community groups, industrial corporations, and governmental agencies regarding the health effects of occupational and environmental exposure to lead. He received no funding from any party for his contributions to this manuscript. B.L.M. and K.L.H. are affiliated with the Occupational Health Branch, California Department of Health Services (CDHS).
